Back to results
US 2018/0000911 A1Published application
Mosquito Saliva Protein Malaria Vaccine
AssigneeYale University
InventorsErol Fikrig, Yang Zhao
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for preventing and treating infection by Plasmodium sporozoites.
Claims15
A vaccine comprising at least one mosquito salivary protein associated with a Plasmodium sporozoite.
A vaccine comprising at least one polypeptide selected from the group consisting of:
- a. AGAP000607-PA, or a AGAP000607-PA variant;
- b. AGAP001374-PA, or a AGAP001374-PA variant;
- c. AGAP009257-PA, or a AGAP009257-PA variant;
- d. AGAP009918-PA, or a AGAP009918-PA variant;
- e. AGAP010750-PA, or a AGAP010750-PA variant;
- f. AGAP001424-PA, or a AGAP001424-PA variant;
- g. AGAP001566-PA, or a AGAP001566-PA variant;
- h. AGAP007347-PA, or a AGAP007347-PA variant;
- i. AGAP008227-PA, or a AGAP008227-PA variant;
- j. AGAP008279-PA, or a AGAP008279-PA variant;
- k. AGAP008283-PA, or a AGAP008283-PA variant;
- l. AGAP011017-PA, or a AGAP011017-PA variant;
- m. AGAP011976-PA, or a AGAP011976-PA variant;
- n. AGAP012081-PA, or a AGAP012081-PA variant;
- o. AGAP013499-PA, or a AGAP013499-PA variant;
- p. AGAP002998-PA, or a AGAP002998-PA variant;
- q. AGAP003937-PA, or a AGAP003937-PA variant;
- r. AGAP004605-PA, or a AGAP004605-PA variant;
- s. AGAP011107-PA, or a AGAP011107-PA variant;
- t. AGAP013013-PA, or a AGAP013013-PA variant;
- u. AGAP009974-PA, or a AGAP009974-PA variant;
- v. AGAP000528-PA, or a AGAP000528-PA variant;
- and
- w. AGAP011026-PA, or a AGAP011026-PA variant.
21 more elements
An inhibitor composition useful for treating, reducing, or preventing Plasmodium sporozoite infection, wherein the inhibitor composition inhibits the interaction between a mosquito salivary protein associated with a Plasmodium sporozoite and the Plasmodium sporozoite.
Dependencies are inferred from the claim text.